- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Offers Investigatorship Awards up to US$500,000 to Outstanding Young Scientists of all Nationalities to Undertake Independent Research in Singapore
Singapore continues to thrive as a vibrant location for scientific talent. Significant efforts and resources have been committed to attract and develop talent. Singapore adopts a pro-international and pro-local approach. A dynamic research environment, robust ethical framework, strict laws for the protection of intellectual property rights (Note 1) and quality of life, are some of the key reasons why a growing number of scientists are drawn to Singapore.
Note 1: Singapore cited as the best location in Asia for the protection
of intellectual property rights. (Source: The International
Property Rights Index (2007))
Over the past five years, Singapore has attracted an impressive list of internationally prominent scientists to lead the nation's biomedical sciences research and development efforts. (Please refer to Annex A for a list of distinguished scientists in Singapore.)
In continuing its efforts to attract talent, Singapore's Agency for Science, Technology & Research (A-STAR) launched A-STAR Investigatorships, a prestigious competitive award aimed at young international postdoctoral fellows who have demonstrated strong ability and creativity in research. Recipients of the award will be given an independent position at one of A-STAR's research institutes and can receive funding of up to US$500,000 per year.
"We invite and encourage the best young scientists of all nationalities to carry out cutting-edge research in Singapore. Recipients of A-STAR Investigatorships will enjoy generous funding, excellent facilities and infrastructure at Biopolis, as well as have the opportunity to be mentored by some of the world's most highly regarded biomedical researchers," said Dr. Andre Wan, Deputy Executive Director, Biomedical Research Council, A-STAR.
This year's call for proposals is in the areas of molecular and cell biology, genetics and genomics research relevant to human diseases and health. Applications are open and the deadline for submission is 31 May 2007.
SINGAPORE, A VIBRANT NODE IN THE INTERNATIONAL RESEARCH & DEVELOPMENT LANDSCAPE
A-STAR investigators will join a vibrant and rapidly growing community of more than 900 scientists and postdoctoral fellows from over 50 countries at the Biopolis, Singapore's premier biomedical research hub.
Partnerships and Collaborations
A-STAR is well connected to the international biomedical research community. Scientists at the institutes work closely with partners in the U.S. (e.g. UCSD, UIUC, UWash, MIT, Fred Hutch CRC), Europe (e.g. Karolinska Institute, Imperial College, Cambridge University, Dundee University, French Atomic Energy Commission) and Australasia (e.g. Australian National University, RIKEN in Japan) on research projects, collaborations and PhD training programs. A-STAR also hosts key international scientific conferences (e.g. Keystone, European Molecular Biology Organization, American Association for Cancer Research) and visits by distinguished scientists including many Nobel laureates.
The National University of Singapore (NUS) and Nanyang Technological University have also been successfully forging international partnerships. Duke University and NUS set up a Graduate Medical School (GMS) in Singapore to nurture clinician-scientists. The GMS will accept its first batch of students in August 2007 and will be awarding joint MD degrees from Duke and NUS.
Translational and Clinical Research
A-STAR works closely with the National Medical Research Council of the Singapore Ministry of Health to develop and strengthen research collaborations and programs between scientists at the Biopolis and the clinical community in hospitals and disease centers. The aim is to translate basic scientific discoveries and innovative technologies into potential therapies and diagnostics that will be applicable to major health conditions such as cancer, cardiovascular diseases, neurological disorders, infectious diseases and eye diseases.
"The scientists of today are incredibly mobile. They can choose to work anywhere in the world. Those who have selected Singapore have told us it is due to a combination of three reasons: steady funding, good facilities and exciting colleagues. We hope the A-STAR Investigatorships will extend this winning combination to the next generation of scientific leaders and persuade them to consider building their careers in Singapore," said Dr. Wan.
To obtain more information, please visit the Singapore Pavilion at booth number 2533.
About Agency for Science, Technology and Research and EDB Singapore
ANNEX A LIST OF DISTINGUISHED SCIENTISTS IN SINGAPORE Industry Name From Designation in Other information Singapore Alex Matter (Dr.) Novartis Director, Novartis Led the Institute for development of Tropical Diseases Gleevec, Novartis' cancer therapeutic blockbuster drug. Alan Colman (Dr.) U.K.-based PPL Chief Executive Well known for Therapeutics, a Officer, ES Cell his work with the spin-off from the International Roslin Institute Roslin Institute to clone Dolly the sheep. Scientific Leaders at A-STAR's Biomedical Research Council Name From Designation in Other information Singapore Sydney Brenner Salk Institute -- Scientific 2002 Nobel prize (Dr.) of Biological Advisor to in Physiology or Studies Chairman, Medicine for A-STAR establishing C. -- Chairman, elegans as a novel Biomedical experimental Research model organism to Council link genetic analysis to cell division, differentiation and organ development. David Lane University of -- Executive One of the (Dr. Sir) Dundee Deputy Chairman, scientists Biomedical credited with Sciences and the landmark Technology, discovery of the Biomedical cancer gene p53. Research Founder of Council Cyclacel, a -- Executive Scottish biotech Director, company. Institute of Molecular and Cell Biology -- Chief Executive Officer, Experimental Therapeutics Centre Edward Holmes University of -- Executive Expert on (Dr.) California San Deputy Chairman, translational Diego Clinical- research and Translational academic medicine. Sciences, Biomedical Research Council. -- Executive Chairman, National Medical Research Council, Ministry of Health Research Institutes Name From Designation in Other information Singapore Edison Liu(Dr.) National Cancer Executive Expert on breast Institute Director, Genome cancer research. Institute of Singapore Jackie Ying(Dr.) Massachusetts Executive Expert on Institute of Director, nanotechnology and Technology Institute of its use in Bioengineering & biotechnology, Nanotechnology medical and chemical sciences. Judith Swain(Dr.) University of Executive Expert on creating California San Director, models to Diego Singapore understand the Institute of genetic basis of Clinical Sciences cardiovascular development and disease. Neal Copeland & National Cancer Principal Renowned cancer Nancy Jenkins Institute Investigators, geneticists who (Drs.) Institute of are among the Molecular and Cell world's most Biology frequently-cited scientists. Philip Ingham University of Principal Expert on (Dr.) Sheffield Investigator, developmental Institute of genetics Molecular and and cell-to-cell Cell Biology communication. Jean Paul Institut Curie Principal Expert on cell Thiery Dr.) Investigator, adhesion and Institute of migration studies. Molecular and Cell Biology Yoshiaki Ito University of Principal Expert on RUNX (Dr.) Kyoto Investigator, genes, a major Institute of tumor suppressor Molecular and associated with Cell Biology gastric cancer. and the National University of Singapore Consortia Name From Designation in Other information Singapore George Radda Department of Chairman, Expert on magnetic (Dr.Sir) Physiology, Singapore resonance in Anatomy and Bioimaging medicine. Genetics, Consortium University of Oxford Philippe College de Chairman, Expert on Kourilsky France Singapore molecular (Dr.) Immunology immunology and Network tumor immunity. Roger Pedersen University of Chairman, Expert on stem (Dr.) Cambridge Singapore Stem cell. Cell Consortium Axel Ullrich Oversees the Director, Founder of (Dr.) molecular Singapore numerous biotech biology OncoGenome companies department, Project including Sugen Max Planck and U3. Institute, Germany For media enquiries, please contact Ruder Finn.
Ruder Finn Binder (Boston)
Ruder Finn Asia (Singapore)
Copyright © PR Newswire Europe LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017